Navigation Links
Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions
Date:2/3/2010

PITTSBURGH, Feb. 3 /PRNewswire/ -- An era of personalized medicine is redefining how patients and doctors work together to fight cancer.  Now, drug response markers such as the ChemoFx® diagnostic test show promising results which can help to determine individual cancer treatment plans when using various chemotherapeutic agents.

ChemoFx® is a test produced by Precision Therapeutics, Inc., a life sciences company in Pittsburgh, Pennsylvania. With the introduction of this innovative drug response marker, the company has pioneered a method of identifying cancer cell response and sensitivity to various chemotherapeutic and biologic agents at the biopsy stage -- long before a patient actually begins chemotherapy -- providing a custom blueprint of a patient's probable tumor response.

The result is valuable insight into which chemotherapy drugs are most likely to work in an individual cancer patient's own body -- along with those that are unlikely to be effective in shrinking and killing the cancerous tumor.  This information can then be used to help guide chemotherapy treatment decisions, according to company officials.

"Patients and their physicians will have an understanding of how chemo will impact the cancer cells themselves long before it impacts the patient," says Sean McDonald, CEO of Precision Therapeutics.  "By testing multiple agents on a patient's cancer cells in the lab, ChemoFx® determines the chemotherapies that are more likely to be effective and avoid those that are likely to be ineffective, giving patients a powerful advantage in their fight against cancer."

The diagnostic test works by taking a sample of a patient's tumor, which is removed during biopsy or surgery, and sending that sample to the Precision Therapeutics laboratory for sensitivity and resistance testing. In a controlled environment that closely parallels what happens within the human body itself, those cells are incubated and treated by a fully automated system with a number of chemotherapy and biologic agents selected by that patient's physician.  Precision Therapeutics then sends the physician a report that details how the cancerous cells responded to each drug or chemotherapy combination. Integrating the results with clinical judgment, the physician can then use the report to support his decision on a treatment regimen for the patient, with the tandem objective of eradicating the disease and optimizing quality of life during chemotherapy treatment.

With the national movement toward cancer patient advocacy gaining momentum, those newly diagnosed are now engaging with their treating physician as both patient -- and partner -- in making cancer treatment decisions.  

"Today's cancer patients are informed, empowered self advocates," according to McDonald.  "They want a voice in their own treatment options.  A key discussion points is the topic of personalizing medicine through testing services such as ChemoFx.  Each and every patient's cancer is unique, making the need for individual, custom drug response markers all the more critical to support a patient's treatment plan. They want their first step to be the right step."

"When you're diagnosed with cancer, your strongest ally is information," says McDonald.  "That means talking with your doctor to plan your best course of action together.  We encourage you to test the tumor first, find out how it responds, and based on those findings and your physicians clinical judgment, determine the optimal treatment plan for your individual cancer."

About Precision Therapeutics

Precision Therapeutics, a life science company and leader in the development of innovative technology, delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions.

For more information, please visit www.precisiontherapeutics.com or www.ChemoFX.com

SOURCE Precision Therapeutics, Inc.

RELATED LINKS
http://www.precisiontherapeutics.com

'/>"/>

SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
4. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
5. Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
6. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
7. Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation
8. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
9. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
10. For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold
11. Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 Research and Markets has ... Forecast to 2021" report to their offering. ... Market growth ... models in the pharmaceutical and biotechnology industry and technological advancements ... funding. Emerging markets and growing research activities in toxicology and ...
(Date:12/9/2016)... -- RxWiki Inc., a digital health company that powers the ... of pharmacies through its Digital Pharmacist SaaS platform, today ... on Fire" Award in the Health and Life Sciences ... award as one of Austin,s fastest growing companies," said ... "Our platform gives independent retail pharmacies the digital tools ...
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and I wanted ... family recipe, which is meant to relieve gout and pain caused by varicose veins. ... energy boost every time. It relieved what VA doctors called the worst sinusitis case ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , ... and other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger ... vice president of sales. , Litsinger joined Mirixa in 2008 after serving ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to ... that are both engaging and easy to use. Coming off the heels of ... revealed today its plans to roll out new AI-powered self-service enhancements to help ...
Breaking Medicine News(10 mins):